CN113499269A - 一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 - Google Patents
一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 Download PDFInfo
- Publication number
- CN113499269A CN113499269A CN202110627397.7A CN202110627397A CN113499269A CN 113499269 A CN113499269 A CN 113499269A CN 202110627397 A CN202110627397 A CN 202110627397A CN 113499269 A CN113499269 A CN 113499269A
- Authority
- CN
- China
- Prior art keywords
- resin
- zinc
- strontium
- hap
- composite resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000805 composite resin Substances 0.000 title claims abstract description 47
- 230000006870 function Effects 0.000 title claims abstract description 12
- 230000009977 dual effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000011347 resin Substances 0.000 claims abstract description 50
- 229920005989 resin Polymers 0.000 claims abstract description 50
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 24
- 239000011159 matrix material Substances 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 21
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 19
- 229910052788 barium Inorganic materials 0.000 claims abstract description 18
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011521 glass Substances 0.000 claims abstract description 18
- 239000011256 inorganic filler Substances 0.000 claims abstract description 17
- 229910003475 inorganic filler Inorganic materials 0.000 claims abstract description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 15
- 239000011701 zinc Substances 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 14
- 229910052712 strontium Inorganic materials 0.000 claims abstract description 14
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000002444 silanisation Methods 0.000 claims abstract description 8
- 238000011049 filling Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 150000003437 strontium Chemical class 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000008367 deionised water Substances 0.000 claims description 24
- 229910021641 deionized water Inorganic materials 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 16
- 239000003999 initiator Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- HWSSEYVMGDIFMH-UHFFFAOYSA-N 2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C HWSSEYVMGDIFMH-UHFFFAOYSA-N 0.000 claims description 10
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 claims description 10
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 10
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims description 10
- 235000019838 diammonium phosphate Nutrition 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 claims description 8
- 159000000008 strontium salts Chemical class 0.000 claims description 8
- 150000003751 zinc Chemical class 0.000 claims description 8
- -1 ethoxylated bisphenol A methacrylate Chemical class 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000005696 Diammonium phosphate Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 239000006087 Silane Coupling Agent Substances 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- UEKHZPDUBLCUHN-UHFFFAOYSA-N 2-[[3,5,5-trimethyl-6-[2-(2-methylprop-2-enoyloxy)ethoxycarbonylamino]hexyl]carbamoyloxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOC(=O)NCCC(C)CC(C)(C)CNC(=O)OCCOC(=O)C(C)=C UEKHZPDUBLCUHN-UHFFFAOYSA-N 0.000 claims description 2
- IISBACLAFKSPIT-UHFFFAOYSA-N Bisphenol A Natural products C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 229930006711 bornane-2,3-dione Natural products 0.000 claims description 2
- 125000002362 bornane-2,3-dione group Chemical group 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims description 2
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims description 2
- 229910000018 strontium carbonate Inorganic materials 0.000 claims description 2
- 229910001631 strontium chloride Inorganic materials 0.000 claims description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 2
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 229960000314 zinc acetate Drugs 0.000 claims description 2
- 235000013904 zinc acetate Nutrition 0.000 claims description 2
- 239000011667 zinc carbonate Substances 0.000 claims description 2
- 235000004416 zinc carbonate Nutrition 0.000 claims description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 2
- 229940043825 zinc carbonate Drugs 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 229960001939 zinc chloride Drugs 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- WHESPEOERJCPHX-UHFFFAOYSA-N C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C)OC=1C(=C(O)C=CC1C(C)(C)C1=CC=C(C=C1)O)OCC Chemical compound C(C(=C)C)(=O)O.C(C(=C)C)(=O)O.C(C)OC=1C(=C(O)C=CC1C(C)(C)C1=CC=C(C=C1)O)OCC WHESPEOERJCPHX-UHFFFAOYSA-N 0.000 claims 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 229940106691 bisphenol a Drugs 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 4
- 210000000214 mouth Anatomy 0.000 abstract description 3
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 230000000395 remineralizing effect Effects 0.000 abstract 1
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 230000008439 repair process Effects 0.000 description 8
- 208000002925 dental caries Diseases 0.000 description 7
- 239000000945 filler Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 4
- 230000033558 biomineral tissue development Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- XIOUDVJTOYVRTB-UHFFFAOYSA-N 1-(1-adamantyl)-3-aminothiourea Chemical compound C1C(C2)CC3CC2CC1(NC(=S)NN)C3 XIOUDVJTOYVRTB-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001723 curing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000011350 dental composite resin Substances 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000000016 photochemical curing Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229910001427 strontium ion Inorganic materials 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229910000645 Hg alloy Inorganic materials 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012767 functional filler Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- CBBVHSHLSCZIHD-UHFFFAOYSA-N mercury silver Chemical compound [Ag].[Hg] CBBVHSHLSCZIHD-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
- A61K6/74—Fillers comprising phosphorus-containing compounds
- A61K6/75—Apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/15—Compositions characterised by their physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/62—Photochemical radical initiators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/70—Preparations for dentistry comprising inorganic additives
- A61K6/71—Fillers
- A61K6/77—Glass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
- A61K6/887—Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Dental Preparations (AREA)
Abstract
本发明涉及一种具有抑菌‑再矿化双功能的齿科修复复合树脂及其制备和应用。该复合树脂包括无机填料、树脂基体和光引发剂,所述无机填料为硅烷化改性的锶/锌单、共掺杂羟基磷灰石纳米颗粒和钡玻璃粉的复配物。该方法使锶/锌掺杂羟基磷灰石良好分散并与树脂基体良好结合,方法简单,成本低廉,对设备要求低,适合规模化生产;所得产品具有持久的抑菌及再矿化能力,颜色不影响美观,生物相容性优异,作为龋齿充填修复材料应用于口腔,将显著改善修复体的远期寿命及疗效。
Description
技术领域
本发明属于齿科修复材料及其制备和应用领域,特别涉及一种具有抑菌及再矿化双功能的齿科修复复合树脂及其制备和应用。
背景技术
龋齿是常见的一种口腔疾病,被世界卫生组织列为21世纪重点防治的三大非传染病之一。龋齿的发病率高,治疗不当会导致口腔多部位炎症,甚至引起关节炎、心肌炎、眼科疾病等其他全身性疾病。银汞合金自19世纪初期开始被人们使用,在齿科修复材料中长期占据着主导地位。但是该种材料存在导热导电、美观性欠佳、生物风险等缺陷,从而限制了其在临床上的应用,逐渐被具有较高机械强度、颜色稳定、美观且生物相容性良好的齿科修复复合树脂所取代。但是,复合树脂材料在长期服役过程中,仍面临力学性能与牙体不匹配、聚合收缩率高等问题,进而引起二次龋齿和修复断裂,导致治疗失败。
复合树脂主要由有机单体、无机填料和少量光引发体系组成,其中有机单体含有可聚合反应的基团,在光固化作用下,形成三维网络结构,可赋予材料一定的形状;无机填料主要赋予复合材料优异的力学性能,同时减少复合树脂的聚合收缩。近年来,齿科修复树脂的研究已取得很大的进展,然而,目前商业化的复合树脂普遍缺乏抑菌性能及再矿化性能,无法有效避免继发龋,且复合树脂修复体与牙齿组织粘结强度提高受限,一定程度影响了其临床修复的远期寿命及疗效。研究表明,继发龋是造成树脂材料修复失败的首要原因。因此,如何赋予口腔复合树脂良好稳定的抑菌性能及再矿化性能以克服继发龋已成为口腔领域亟待解决的难题之一。
以往的研究通过向树脂中直接添加氯己定、氟化物、银离子等抑菌剂来赋予流动树脂抑菌性能,这种方法简单易行,但由于抑菌成分仅仅是物理溶解于材料中,抑菌作用通过抑菌剂的析出来实现,因此容易引起“突释效应”,抑菌性能通常维持时间较短,且存在对引起细胞毒性的担忧。也有研究通过向复合树脂中添加羟基磷灰石、磷酸三钙、硅酸钙等无机填料来赋予树脂再矿化性能,相比于溶解速率较快的磷酸三钙和硅酸钙等易引起树脂修复体力学性能下降,羟基磷灰石作为人体骨骼和牙釉质的主要无机成分,是作为复合树脂无机填料的一个很好的选择,备受广大研究者的青睐,但这类改性树脂仍缺乏抑菌性能。
人工合成的纳米羟基磷灰石与牙齿中羟基磷灰石的组成相近,用作牙釉质再矿化材料是当前口腔防龋材料研究的热点之一。但作为复合树脂的无机填料,由于高结晶性的纯羟基磷灰石离子溶出速率慢,促生物矿化性能相对有限,而且纯羟基磷灰石也不具有抑菌生物活性。所以,对人工合成的纳米羟基磷灰石无机填料进行功能化改性,提高其生物矿化活性的同时,赋予其抑菌生物活性,作为一种新策略对于发展具有抑菌及再矿化双功能的齿科修复复合树脂,以达到提高龋齿填充修复效果、延长其临床使用寿命、减轻国民医疗经济负担、减少患者所受病痛的最终目标有显著的积极意义。
发明内容
本发明所要解决的技术问题是提供一种具有抑菌-再矿化双功能的齿科修复复合树脂及制备方法,该方法选用天然骨中存在的微量元素锶和锌,利用锶离子的促生物矿化活性和锌离子的抑菌生物活性,通过共沉淀法制备锶/锌单、共掺杂羟基磷灰石纳米颗粒,并使其作为功能填料与传统齿科复合树脂填料钡玻璃粉复配,在光固化树脂基体中良好分散并与树脂基体良好结合,得到具有持久的抑菌及再矿化能力的齿科修复复合树脂。
本发明的一种具有抑菌-再矿化双功能的齿科修复复合树脂,包括无机填料、树脂基体和光引发剂,所述无机填料为硅烷化改性的锶/锌单、共掺杂纳米羟基磷灰石Sr/Zn-HAp颗粒和钡玻璃粉的复配物,无机填料占齿科复合树脂总质量的60-80%,其中硅烷化改性的Sr/Zn-HAp颗粒和钡玻璃粉的质量比为1:5-20。
所述树脂基体和光引发剂为复合树脂总质量的20-40%,光引发剂为树脂基体质量的1.0-3.0%。
所述树脂基体由质量比为1-5:1的主体树脂和稀释树脂组成。
所述主体树脂为双酚A-甲基丙烯酸缩水甘油酯Bis-GMA、氨基甲酸酯双甲基丙烯酸缩水甘油酯UDMA中的一种或两种。
所述稀释树脂为双乙氧基双酚-A二甲基丙烯酸酯EBPADMA、二甲基丙烯酸三乙二醇酯TEGDMA、乙氧化双酚A甲基丙烯酸酯BPA4EODMA、双酚A乙烯醇二丙烯酸甲酯Bis-EMA中的一种或几种。
优选的,所述树脂基体为质量比1-5:1的双酚A-甲基丙烯酸缩水甘油酯Bis-GMA,以及二甲基丙烯酸三乙二醇酯TEGDMA。
所述引发剂由质量比为1:1-2的主引发剂和助引发剂组成。
所述主引发剂为樟脑醌CQ,助引发剂为甲基丙烯酸二甲基乙酯DMAEMA。
所述Sr/Zn-HAp粒径为200-600nm,锶/锌取代羟基磷灰石中钙离子的摩尔百分比为5-15%,优选为15%,其中,锶和锌的取代比例为0:1-1:0。
所述钡玻璃粉粒径为400-700nm。
本发明还提供一种具有抑菌-再矿化双功能的齿科修复复合树脂的制备方法,包括:
(1)将磷酸氢二铵溶于去离子水配置成溶液,调节溶液pH值为9-13,同时称取硝酸钙溶于去离子水配置成硝酸钙溶液,称取锶盐或锌盐配置成锶盐和锌盐水溶液,然后将硝酸钙溶液和锶盐或锌盐溶液中的一种或两种滴加入磷酸氢二铵溶液,在50-90℃反应1-6小时,反应结束后通过离心操作收集Sr/Zn-HAp颗粒,去离子水洗涤后干燥备用;
(2)将硅烷偶联剂KH570加入乙醇水溶液,用乙酸调节pH值为2-4,超声1小时,得到KH570水解液,其中,KH570、乙醇和去离子水的体积比为1:30-50:15-5;
(3)将步骤(1)获得的Sr/Zn-HAp颗粒与无水乙醇混合,200-400W超声10-30分钟分散得到均匀悬浮液后,加入步骤(2)配置的KH570水解液,恒温在50℃反应24小时,反应完成后通过离心操作收集硅烷化改性Sr/Zn-HAp颗粒,去离子水洗涤后干燥备用;
(4)将主体树脂、稀释树脂和光引发剂按比例混合均匀,备用;
(5)将步骤(2)制备的硅烷化改性Sr/Zn-HAp颗粒、钡玻璃粉和步骤(4)配置的树脂基体,按比例混合均匀,减压除去树脂糊的气泡,即得到一种具有抑菌-再矿化双功能的齿科修复复合树脂。
所述步骤(1)中锶盐或锌盐为硝酸锶、醋酸锶、氯化锶、碳酸锶、硝酸锌、碳酸锌、氯化锌、醋酸锌、柠檬酸锌、葡萄糖酸锌中的一种或几种。
所述步骤(3)中钡玻璃粉为400-700nm。
本发明用锶/锌离子取代羟基磷灰石中部分钙离子合成掺杂程度不同的Sr/Zn-HAp,硅烷化改性后与钡玻璃粉复配作为齿科修复树脂填料。Sr/Zn-HAp填料通过释放锶/锌离子可以增强复合树脂的再矿化和抑菌性能,为解决复合树脂在服役过程中存在的继发龋问题提供策略。
有益效果
1.本发明的Sr/Zn-HAp制备工艺简单,制备条件温和,不仅所制备的Sr/Zn-HAp化学组成、晶型和尺寸可控,还适合大批量生产;
2.本发明的Sr/Zn-HAp经硅烷偶联剂KH570改性后,可在树脂基体中分散良好,并且KH570所带有的可参与树脂光固化反应的丙烯酸酯官能团,使Sr/Zn-HAp颗粒与树脂基体结合紧密,在优化的添加量下,不会因Sr/Zn-HAp纳米颗粒发生团聚,从而对复合树脂的力学性能产生不利影响;
3.将Sr/Zn-HAp纳米颗粒与具有较宽粒径分布和较大粒径的硅烷化钡玻璃粉按不同比例复配作为复合树脂的填料,首先,不同尺度的填料将显示出多尺度增强的优势,相比于单一采用硅烷化钡玻璃粉作为填料的体系,提高了复合树脂的力学性能;其次,适量锶离子从复合树脂的释放,为矿物质沉积提供了成核位点,促进了矿物质沉积;第三,适量锌离子从复合树脂的释放,在保证生物相容的前提下,赋予复合树脂一定的抑菌活性。由此,具有增强再矿化和抑菌活性的双功能复合树脂,应用于龋齿的填充修复,其长期服役性能得到有效地提高。
附图说明
图1为本发明实施例1中取代摩尔百分比为15%的Sr-HAp,实施例2中取代摩尔百分比为15%的Zn-HAp和实施例3中取代摩尔百分比为15%的Sr/Zn-HAp的SEM图像;
图2为本发明实施例1中15%Sr-HAp和实施例2中5-15%Zn-HAp的细菌生长情况图;
图3为本发明实施例1中15%Sr-HAp和实施例2中5-15%Zn-HAp的CFU形成数量图;
图4为本发明实施例1中15%Sr-HAp和实施例2中5-15%Zn-HAp的抗菌率表征图;
图5为本发明实施例4得到复合树脂的再矿化表征图;
图6为本发明实施例4、5得到复合树脂的细胞相容性表征图。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施例中所描述的内容仅用于说明本发明,而不应当也不会限制权利要求书中说描述的本发明。
性能评价:
(1)抑菌性能
将20mg Sr/Zn-HAp纳米颗粒粉末与1mL菌液混合,加入24孔板中,于37℃培养24小时后,取出孔板中的液体稀释105倍数后均匀涂抹在LB琼脂培养基上,继续在37℃下培养24小时,观察各个平板上的细菌生长情况,计算CFU数量和抗菌率。抗菌率(AR)(Antibacterial ratio)的计算公式如下:
其中,N0是空白样品平板中的菌落数目,N1为涂抹抑菌溶液后平板中的菌落数目,实验重复三次取平均值。
(2)再矿化性能
1.5倍SBF的配置:称取11.994g NaCl、0.5292g NaHCO3、0.1065g Na2SO4、0.3354gKCl、0.3423g K2HPO4·3H2O、0.4568g MgCl2·6H2O和0.3413g CaCl2·2H2O依次分批加入37℃去离子水中,待前一个药品溶解后,再加入后一个药品,并使用Tris-HCl调节pH至7.4,最后用去离子水定容至1000mL待用。
将制备好的复合树脂材料放入直径12mm、高2mm的模具内,用可见光固化灯将上下两面分别固化60秒。从模具中取出已固化的试样,浸泡入1.5倍SBF溶液中,置于37℃恒温水浴摇床中,1天后,干燥,扫描电镜下观察表面矿化情况。
(3)细胞毒性评价
将制备好的复合树脂材料放入直径12mm、高2mm的模具内,用可见光固化灯将上下两面分别固化60秒,从模具中取出已固化的试样。将试样浸泡在75%的医用酒精当中,在紫外灯下照射4小时,其间每隔2小时更换一次酒精,随后使用PBS清洗树脂样品3次,每次间隔30分钟。以细胞培养基与树脂试样的体积/标准表面积=1mL:1.25cm2制备浸提液进行L929成纤维细胞培养,评估树脂的生物相容性。将配好的细胞悬液加入96孔板中,放进恒温CO2培养箱中(37℃,5%CO2)孵育2小时,待细胞贴附好,再替换成浸提液,继续共培养,在1天和3天进行取样,从培养箱中取出96孔板孔板,吸去孔板内原有的培养基,每孔加入200μLCCK-8工作液(将1mL CCK-8加入9mL新鲜培养基中配制而成,现用现配),将96孔板放回培养箱中;孵育4小时后,从96孔板的各个孔中各吸取100μL液体加到酶标板中,放入酶标仪,测量450nm下的吸光度值。
实施例1
(1)Sr-HAp纳米颗粒的制备
称取磷酸氢二铵4.25g,倒入装有100mL去离子水的三口烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解,用氨水调节pH=10,称取四水合硝酸钙10.03g、硝酸锶1.59g,倒入装有100mL去离子水的烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解后,滴加到三口烧瓶中,保持反应体系pH=10,滴加结束后,继续搅拌5小时。反应结束后用去离子水离心洗涤,干燥,即得到钙取代摩尔百分比为15%的Sr-HAp。
(2)Sr-HAp的硅烷化改性
量取90mL乙醇、10mL去离子水、2.5mLKH570于250mL烧杯中,超声15min,加入乙酸调节pH=3,超声水解1小时,同时,称取2g Sr-HAp粉末悬浮于15mL乙醇中,200W功率超声分散15分钟后,将混合液倒入前述KH570水解液中,恒温50℃反应24小时。反应完成后,去离子水离心洗涤,干燥得硅烷化改性的钙取代摩尔百分比为15%Sr-HAp颗粒。
实施例2
(1)Zn-HAp纳米颗粒的制备
称取磷酸氢二铵4.25g,倒入装有100mL去离子水的三口烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解,用氨水调节pH=10,称取四水合硝酸钙10.03g、六水合硝酸锌2.23g,倒入装有100mL去离子水的烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解后,滴加到三口烧瓶中,保持反应体系pH=10,滴加结束后,继续搅拌3小时。反应结束后用去离子水离心洗涤,干燥,即得到钙取代摩尔百分比为15%的Zn-HAp。
(2)Zn-HAp的硅烷化改性
将实施例1步骤(2)中的Sr-HAp颗粒换成Zn-HAp颗粒,得到硅烷化改性的钙取代摩尔百分比为15%Zn-HAp颗粒。
实施例3
(1)锶/锌共掺杂羟基磷灰石Sr/Zn-HAp纳米颗粒的制备
称取磷酸氢二铵4.25g,倒入装有100mL去离子水的三口烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解,用氨水调节pH=10,称取四水合硝酸钙10.03g、硝酸锶0.79g、六水合硝酸锌1.12g,倒入装有100mL去离子水的烧瓶中,加入磁子在90℃油浴锅中搅拌至完全溶解后,滴加到三口烧瓶中,保持反应体系pH=10,滴加结束后,继续搅拌3小时。反应结束后用去离子水离心洗涤,干燥,即得到锶/锌掺杂比例为1:1、钙取代摩尔百分比为15%Sr/Zn-HAp颗粒。
(2)Sr/Zn-HAp颗粒的硅烷化改性
与实施例1中步骤(2)相同,得到硅烷化改性的Sr/Zn-HAp颗粒。
实施例4
将0.8g实施例1中硅烷化改性15%Sr-HAp和6.2g钡玻璃粉,混合树脂基体(1.764gBis-GMA和1.176g TEGDMA)与引发剂(0.03g CQ和0.03g DMAEMA)通过三辊研磨机混合均匀,得到未固化树脂糊剂,最后经光固化制得复合树脂。
实施例5
将0.8g实施例2中硅烷化改性15%Zn-HAp和6.2g钡玻璃粉,混合树脂基体(1.764gBis-GMA和1.176g TEGDMA)与引发剂(0.03g CQ和0.03g DMAEMA)通过三辊研磨机混合均匀,得到未固化树脂糊剂,最后经光固化制得复合树脂。
实施例6
将0.4g实施例1中硅烷化改性15%Sr-HAp、0.4g实施例2中硅烷化改性15%Zn-HAp和6.2g钡玻璃粉,混合树脂基体(1.764g Bis-GMA和1.176g TEGDMA)与引发剂(0.03g CQ和0.03g DMAEMA)通过三辊研磨机混合均匀,得到未固化树脂糊剂,最后经光固化制得复合树脂。
实施例7
将0.8g实施例3中硅烷化改性15%Sr/Zn-HAp和6.2g钡玻璃粉,混合树脂基体(1.764g Bis-GMA和1.176g TEGDMA)与引发剂(0.03g CQ和0.03g DMAEMA)通过三辊研磨机混合均匀,得到未固化树脂糊剂,最后经光固化制得复合树脂。
Claims (6)
1.一种具有抑菌-再矿化双功能的齿科修复复合树脂,包括无机填料、树脂基体和光引发剂,其特征在于,所述树脂基体由质量比为(1-5):1的主体树脂和稀释树脂组成,所述无机填料为硅烷化改性的锶/锌单、共掺杂羟基磷灰石纳米颗粒Sr/Zn-HAp和钡玻璃粉的复配物,锶/锌取代羟基磷灰石中钙离子的摩尔百分比为5%-15%,其中,锶和锌的取代比例为0:1-1:0,Sr/Zn-HAp粒径为200-600nm,钡玻璃粉粒径为400-700nm,按质量百分比,无机填料与树脂基体的重量比为60:40-80:20,其中硅烷化改性的Sr/Zn-HAp和钡玻璃粉的质量比为1:5-20,光引发剂为树脂基体质量的1.0-3.0%。
2.根据权利要求1所述一种具有抑菌-再矿化双功能的齿科修复复合树脂,其制备方法包括以下步骤:
(1)将磷酸氢二铵溶于去离子水配置成溶液,调节溶液pH值为9-13,同时称取硝酸钙溶于去离子水配置成硝酸钙溶液,称取锶盐或锌盐配置成锶盐和锌盐水溶液,然后将硝酸钙溶液和锶盐或锌盐溶液中的一种或两种滴加入磷酸氢二铵溶液,在50-90℃反应1-6小时,反应结束后通过离心操作收集Sr/Zn-HAp颗粒,去离子水洗涤后干燥备用;
(2)将硅烷偶联剂KH570加入乙醇水溶液,乙醇水溶液为乙醇和去离子水混合而成,用乙酸调节pH值为2-4,超声1小时,得到KH570水解液,其中,KH570、乙醇和去离子水的体积比为1:30-50:15-5;
(3)将步骤(1)获得的Sr/Zn-HAp颗粒与无水乙醇混合,100-400W超声10-30分钟分散得到均匀悬浮液后,加入步骤(2)配置的KH570水解液,恒温在50℃反应24小时,反应完成后通过离心操作收集硅烷化改性Sr/Zn-HAp颗粒,去离子水洗涤后干燥备用;
(4)将主体树脂、稀释树脂和光引发剂混合均匀备用;
(5)将步骤(2)制备的硅烷化改性Sr/Zn-HAp、钡玻璃粉和步骤(4)配置的树脂基体,混合均匀,减压除去树脂糊的气泡,即得到一种具有抑菌-再矿化双功能的齿科修复复合树脂。
3.根据权利要求1所述复合树脂,其特征在于,所述主体树脂为双酚A-甲基丙烯酸缩水甘油酯Bis-GMA、氨基甲酸酯双甲基丙烯酸缩水甘油酯UDMA中的一种或两种,稀释树脂为双乙氧基双酚-A二甲基丙烯酸酯EBPADMA、二甲基丙烯酸三乙二醇酯TEGDMA、乙氧化双酚A甲基丙烯酸酯BPA4EODMA、双酚A乙烯醇二丙烯酸甲酯Bis-EMA中的一种或几种。
4.根据权利要求1所述复合树脂,其特征在于,所述光引发剂由质量比为1:1-2的主引发剂和助引发剂组成,所述主引发剂为樟脑醌CQ,助引发剂为甲基丙烯酸二甲基乙酯DMAEMA。
5.根据权利要求2中所述复合树脂,其特征在于,所述步骤(1)中锶盐或锌盐为硝酸锶、醋酸锶、氯化锶、碳酸锶、硝酸锌、碳酸锌、氯化锌、醋酸锌、柠檬酸锌、葡萄糖酸锌中的一种或几种。
6.权利要求1所述复合树脂作为光固化粘结修复材料在牙齿缺损填充修复中应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110627397.7A CN113499269A (zh) | 2021-06-05 | 2021-06-05 | 一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110627397.7A CN113499269A (zh) | 2021-06-05 | 2021-06-05 | 一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113499269A true CN113499269A (zh) | 2021-10-15 |
Family
ID=78009062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110627397.7A Pending CN113499269A (zh) | 2021-06-05 | 2021-06-05 | 一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113499269A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115957137A (zh) * | 2022-12-23 | 2023-04-14 | 北京大学口腔医学院 | 用于长效抗细菌粘附的组合物及方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564357A (zh) * | 2009-06-02 | 2009-10-28 | 李榕卿 | 一种牙用光固化组合物 |
CN109010079A (zh) * | 2018-09-04 | 2018-12-18 | 东华大学 | 海胆状多晶须羟基磷灰石增强齿科修复树脂的制备方法 |
CN109199873A (zh) * | 2017-07-06 | 2019-01-15 | 北京化工大学 | 一种用于齿科修复树脂的无机纳米粒子团簇体及其制备方法 |
CN109481317A (zh) * | 2017-09-11 | 2019-03-19 | 北京化工大学 | 一种齿科修复用纳米复合树脂及其制备方法 |
CN111991241A (zh) * | 2020-09-03 | 2020-11-27 | 东华大学 | 一种类“驴欺口”花球状氟化羟基磷灰石基齿科复合树脂及其制备方法 |
-
2021
- 2021-06-05 CN CN202110627397.7A patent/CN113499269A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101564357A (zh) * | 2009-06-02 | 2009-10-28 | 李榕卿 | 一种牙用光固化组合物 |
CN109199873A (zh) * | 2017-07-06 | 2019-01-15 | 北京化工大学 | 一种用于齿科修复树脂的无机纳米粒子团簇体及其制备方法 |
CN109481317A (zh) * | 2017-09-11 | 2019-03-19 | 北京化工大学 | 一种齿科修复用纳米复合树脂及其制备方法 |
CN109010079A (zh) * | 2018-09-04 | 2018-12-18 | 东华大学 | 海胆状多晶须羟基磷灰石增强齿科修复树脂的制备方法 |
CN111991241A (zh) * | 2020-09-03 | 2020-11-27 | 东华大学 | 一种类“驴欺口”花球状氟化羟基磷灰石基齿科复合树脂及其制备方法 |
Non-Patent Citations (3)
Title |
---|
罗娟等: "纳米增韧牙科复合树脂的研究", 《临床口腔医学杂志》 * |
马野等: "光固化镁掺杂羟基磷灰石复合树脂的力学性能研究", 《佳木斯大学学报(自然科学版)》 * |
马野等: "镁掺杂羟基磷灰石复合树脂的制备及抗菌性能研究", 《中国体视学与图像分析》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115957137A (zh) * | 2022-12-23 | 2023-04-14 | 北京大学口腔医学院 | 用于长效抗细菌粘附的组合物及方法 |
CN115957137B (zh) * | 2022-12-23 | 2023-09-12 | 北京大学口腔医学院 | 用于长效抗细菌粘附的组合物及方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Functional fillers for dental resin composites | |
Bapat et al. | An overview of application of silver nanoparticles for biomaterials in dentistry | |
Khoroushi et al. | A review of glass-ionomers: From conventional glass-ionomer to bioactive glass-ionomer | |
Kim et al. | Sol–gel-derived bioactive glass nanoparticle-incorporated glass ionomer cement with or without chitosan for enhanced mechanical and biomineralization properties | |
Park et al. | Current aspects and prospects of glass ionomer cements for clinical dentistry | |
CN109453034B (zh) | 一种抗菌齿科修复复合树脂及其制备和应用 | |
Chen et al. | Surface modification of urchin-like serried hydroxyapatite with sol-gel method and its application in dental composites | |
EP0832636B1 (de) | Polymerisierbarer Dentalwerkstoff und Verwendung von Apatit-Füllstoffen im Dentalwerkstoff | |
WO2005115305A1 (de) | Gluszusammensetzungen als antimikrobieller zusatz für dentalmaterialien | |
EP1119337A1 (de) | Dentalwerkstoff aufweisend poröse glaskeramiken | |
Nguyen et al. | Dental cement's biological and mechanical properties improved by ZnO nanospheres | |
US9427381B2 (en) | Dental curable composition, and method for producing same | |
CN103690376B (zh) | 牙髓根管充填糊剂 | |
CN112057348B (zh) | 一种牙齿封闭处理的多重组合物 | |
Hasan | Evaluation the properties of orthodontic adhesive incorporated with nano-hydroxyapatite particles | |
CN110859755A (zh) | 一种用于治疗牙髓病变的盖髓剂及其制备方法和用途 | |
CN110169948A (zh) | 一种含生物活性矿物质材料的口腔溃疡修复凝胶及其制备方法 | |
CN103040631B (zh) | 一种抗菌型无机晶须功能复合材料及其制法和用途 | |
Najeeb et al. | Nano glass ionomer cement: Modification for biodental applications | |
CN113499269A (zh) | 一种具有抑菌-再矿化双功能的齿科修复复合树脂及其制备和应用 | |
CN110507547B (zh) | 一种基于生物活性玻璃/壳聚糖的复合活髓保存材料及其制备方法与应用 | |
Karimi et al. | Effect of synthetic amorphous calcium phosphate nanoparticles on the physicochemical and biological properties of resin-modified glass ionomer cements | |
CN111991241B (zh) | 一种类“驴欺口”花球状氟化羟基磷灰石基齿科复合树脂及其制备方法 | |
Deliormanlı | Investigation of in vitro mineralization of silicate-based 45S5 and 13-93 bioactive glasses in artificial saliva for dental applications | |
Makanjuola et al. | A new hydrolytic route to an experimental glass for use in bioactive glass-ionomer cement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211015 |